William Harvey Research Conference on PDE inhibitors: drugs with an expanding range of therapeutic uses
Author:
- 1 March 2000
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 9 (3) , 621-625
Abstract
Presentations at the William Harvey Research Conference on PDE Inhibitors described the molecular biology, biochemical regulation. pharmacology, and therapeutic utility of inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Most of the talks focused on PDE4 and PDE5. two members of the 11-member PDE family that have attracted much interest over the last several years. These enzymes have been shown to be targets for drugs with wide-ranging clinical utility, including treatment of inflammation, depression, and male erectile dysfunction. The continued investigation of PDEs and the development of potent and selective inhibitors should provide even more therapeutic agents in years to come.Keywords
This publication has 7 references indexed in Scilit:
- Synthesis and structure–activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitorsBioorganic & Medicinal Chemistry Letters, 2000
- Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient miceProceedings of the National Academy of Sciences, 1999
- The Molecular Biology of Cyclic Nucleotide Phosphodiesterases1999
- cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular modelBiochemical Journal, 1998
- The Multienzyme PDE4 Cyclic Adenosine Monophosphate–Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions1998
- Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP PhosphodiesterasesCellular Signalling, 1997
- New Cardiac DrugsInternational Anesthesiology Clinics, 1995